Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Other Accumulated Expenses (2020 - 2023)

Candel Therapeutics' Other Accumulated Expenses history spans 4 years, with the latest figure at $48000.0 for Q3 2023.

  • For Q3 2023, Other Accumulated Expenses rose 54.84% year-over-year to $48000.0; the TTM value through Sep 2023 reached $48000.0, up 54.84%, while the annual FY2022 figure was $48000.0, 85.63% down from the prior year.
  • Other Accumulated Expenses for Q3 2023 was $48000.0 at Candel Therapeutics, roughly flat from $48000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $334000.0 in Q4 2021 and bottomed at $31000.0 in Q3 2022.
  • The 4-year median for Other Accumulated Expenses is $63000.0 (2022), against an average of $123090.9.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 78.61% in 2021 before it tumbled 86.46% in 2022.
  • A 4-year view of Other Accumulated Expenses shows it stood at $187000.0 in 2020, then surged by 78.61% to $334000.0 in 2021, then plummeted by 85.63% to $48000.0 in 2022, then changed by 0.0% to $48000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Other Accumulated Expenses are $48000.0 (Q3 2023), $48000.0 (Q2 2023), and $48000.0 (Q1 2023).